WO2003086470A3 - Smac-peptides as therapeutics against cancer and autoimmune diseases - Google Patents

Smac-peptides as therapeutics against cancer and autoimmune diseases Download PDF

Info

Publication number
WO2003086470A3
WO2003086470A3 PCT/EP2003/004039 EP0304039W WO03086470A3 WO 2003086470 A3 WO2003086470 A3 WO 2003086470A3 EP 0304039 W EP0304039 W EP 0304039W WO 03086470 A3 WO03086470 A3 WO 03086470A3
Authority
WO
WIPO (PCT)
Prior art keywords
smac
cancer
cells
autoimmune diseases
peptides
Prior art date
Application number
PCT/EP2003/004039
Other languages
French (fr)
Other versions
WO2003086470A2 (en
Inventor
Klaus Michael Debatin
Simone Fulda
Original Assignee
Deutsches Krebsforsch
Klaus Michael Debatin
Simone Fulda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02008199A external-priority patent/EP1354952A1/en
Priority claimed from EP02015499A external-priority patent/EP1354953A1/en
Application filed by Deutsches Krebsforsch, Klaus Michael Debatin, Simone Fulda filed Critical Deutsches Krebsforsch
Priority to US10/511,037 priority Critical patent/US20050222387A1/en
Priority to AU2003236211A priority patent/AU2003236211A1/en
Priority to EP03722503A priority patent/EP1495124A2/en
Priority to JP2003583486A priority patent/JP2005536457A/en
Publication of WO2003086470A2 publication Critical patent/WO2003086470A2/en
Publication of WO2003086470A3 publication Critical patent/WO2003086470A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention is directed to the use of Smac to sensitize different tumors and self-reactive immune cells to various pro-apoptosic stimuli, in that the cells subsequently undergo apoptosis. Therefore, Smac can be used as a compound for the manufacture of a medicament for the treatment of cancer and autoimmune diseases. Sensitization of the cells is achieved either by applying a cell-permeable form of Smac combined with known anticancer agents or by overexpression of the protein. It is an object of the invention to provide a new method in cancer and autoimmune disease therapy by using Smac agonists for apoptosis regulation. Thus, Smac agonists represent novel promising cancer and autoimmune disease therapeutics to potentiate the efficacy of cytotoxic therapies even in resistant tumors and immune cells.
PCT/EP2003/004039 2002-04-17 2003-04-17 Smac-peptides as therapeutics against cancer and autoimmune diseases WO2003086470A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/511,037 US20050222387A1 (en) 2002-04-17 2003-04-17 Smac-peptides as therapeutics against cancer and autoimmune diseases
AU2003236211A AU2003236211A1 (en) 2002-04-17 2003-04-17 Smac-peptides as therapeutics against cancer and autoimmune diseases
EP03722503A EP1495124A2 (en) 2002-04-17 2003-04-17 Smac-peptides as therapeutics against cancer and autoimmune diseases
JP2003583486A JP2005536457A (en) 2002-04-17 2003-04-17 Smac-peptides as therapeutics for cancer and autoimmune diseases

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP02008199A EP1354952A1 (en) 2002-04-17 2002-04-17 Smac-peptides as therapeutics against cancer and autoimmune diseases
EP02008199.8 2002-04-17
EP02015499A EP1354953A1 (en) 2002-04-17 2002-07-12 Smac-peptides as therapeutics against cancer and autoimmune diseases
EP02015499.3 2002-07-12
EP03722503A EP1495124A2 (en) 2002-04-17 2003-04-17 Smac-peptides as therapeutics against cancer and autoimmune diseases

Publications (2)

Publication Number Publication Date
WO2003086470A2 WO2003086470A2 (en) 2003-10-23
WO2003086470A3 true WO2003086470A3 (en) 2004-05-06

Family

ID=33458041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004039 WO2003086470A2 (en) 2002-04-17 2003-04-17 Smac-peptides as therapeutics against cancer and autoimmune diseases

Country Status (2)

Country Link
EP (1) EP1495124A2 (en)
WO (1) WO2003086470A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076366B2 (en) 2009-01-15 2011-12-13 Cephalon, Inc. Forms of bendamustine free base

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309792B2 (en) 2004-03-01 2007-12-18 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
WO2005094818A1 (en) 2004-03-23 2005-10-13 Genentech, Inc. Azabicyclo-octane inhibitors of iap
US7244851B2 (en) 2004-07-02 2007-07-17 Genentech, Inc. Inhibitors of IAP
DK1836201T4 (en) 2004-12-20 2013-11-11 Genentech Inc Pyrrolidine Inhibitors of IAP.
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
EP1973899A4 (en) 2005-12-19 2010-10-20 Genentech Inc Inhibitors of iap
TWI504597B (en) 2006-03-16 2015-10-21 Pharmascience Inc Iap bir domain binding compounds
US7807699B2 (en) 2006-03-21 2010-10-05 Joyant Pharmaceuticals, Inc. Dimeric pyrrolidine amide-containing small molecule apoptosis promoters
WO2008079735A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of iap
MX2009010667A (en) 2007-04-12 2010-02-24 Joyant Pharmaceuticals Inc Smac mimetic dimers and trimers useful as anti-cancer agents.
NZ580226A (en) 2007-04-30 2012-11-30 Genentech Inc Dimer compounds as inhibitors of iap
AR072777A1 (en) 2008-03-26 2010-09-22 Cephalon Inc SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE
CA2730448A1 (en) 2008-08-02 2010-02-11 Genentech, Inc. Inhibitors of iap
CA2735899A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
EP2784076A1 (en) 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
US20200199624A1 (en) * 2017-05-19 2020-06-25 Georgia State University Research Foundation, Inc. Recombinant oncolytic virus

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004686A1 (en) * 1992-08-21 1994-03-03 Biogen, Inc. Tat-derived transport polypeptides
WO1999005302A1 (en) * 1997-07-24 1999-02-04 The Perkin-Elmer Corporation Conjugates of transporter peptides and nucleic acid analogs, and their use
WO2000029427A2 (en) * 1998-11-13 2000-05-25 Cyclacel Limited Antennapedia homeodomain helix 3 derived translocation vectors
WO2000058488A2 (en) * 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
JP2001046070A (en) * 1999-08-05 2001-02-20 Japan Science & Technology Corp Transporter using cystine, basic amino acid and neutral amino acid as substrate, and gene coding for the same
WO2001038547A2 (en) * 1999-11-24 2001-05-31 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
WO2001049719A2 (en) * 2000-01-06 2001-07-12 Board Of Regents, The University Of Texas System Activators of caspases
US6306613B1 (en) * 1997-02-26 2001-10-23 Ciblex Corporation Modulators of leaderless protein export and methods for identifying and using the same
WO2002016402A2 (en) * 2000-08-23 2002-02-28 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002016418A2 (en) * 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002026775A2 (en) * 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004686A1 (en) * 1992-08-21 1994-03-03 Biogen, Inc. Tat-derived transport polypeptides
EP0903408A2 (en) * 1992-08-21 1999-03-24 Biogen, Inc. Tat-derived transport polypeptide
US6306613B1 (en) * 1997-02-26 2001-10-23 Ciblex Corporation Modulators of leaderless protein export and methods for identifying and using the same
WO1999005302A1 (en) * 1997-07-24 1999-02-04 The Perkin-Elmer Corporation Conjugates of transporter peptides and nucleic acid analogs, and their use
WO2000029427A2 (en) * 1998-11-13 2000-05-25 Cyclacel Limited Antennapedia homeodomain helix 3 derived translocation vectors
WO2000058488A2 (en) * 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
JP2001046070A (en) * 1999-08-05 2001-02-20 Japan Science & Technology Corp Transporter using cystine, basic amino acid and neutral amino acid as substrate, and gene coding for the same
WO2001038547A2 (en) * 1999-11-24 2001-05-31 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
WO2001049719A2 (en) * 2000-01-06 2001-07-12 Board Of Regents, The University Of Texas System Activators of caspases
WO2002016402A2 (en) * 2000-08-23 2002-02-28 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002016418A2 (en) * 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002026775A2 (en) * 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1, 7 December 2001 (2001-12-07), ORLANDO, FLORIDA, USA *
92nd Annual Meeting of the American Association for Cancer Research; New Orleans, LA, USA; March 24-28, 2001 *
93rd Annual Meeting of the American Association for Cancer Research; San Francisco, California, USA; April 06-10, 2002 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2001, ENDO, HITOSHI ET AL: "Cysteine, basic and neutral amino acid transporter BAT1 from rat and human activated by rBAT, cDNA, and recombinant expression", XP002204777, retrieved from STN Database accession no. 134:174559 HCA *
DEROSSI D ET AL: "TROJAN PEPTIDES: THE PENETRATIN SYSTEM FOR INTRACELLULAR DELIVERY", TRENDS IN CELL BIOLOGY, ELSEVIER SCIENCE LTD, XX, vol. 8, February 1998 (1998-02-01), pages 84 - 87, XP002940006, ISSN: 0962-8924 *
EKERT P G ET AL.: "DIABLO promotes apoptosis by removing MIHA/XIAP from processed caspase 9", JOURNAL OF CELL BIOLOGY, vol. 153, no. 3, 30 April 2001 (2001-04-30), pages 483 - 490, XP002272041, ISSN: 0021-9525 *
FISCHER P M ET AL: "STRUCTURE-ACTIVITY RELATIONSHIP OF TRUNCATED AND SUBSTITUTED ANALOGUES OF THE INTRACELLULAR DELIVERY VECTOR PENETRATIN", JOURNAL OF PEPTIDE RESEARCH, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 55, no. 2, February 2000 (2000-02-01), pages 163 - 172, XP000899124, ISSN: 1397-002X *
FULDA SIMONE ET AL: "Release of Smac from mitochondria bypasses the Bcl-2 inhibition in type II cells and sensitizes for death receptor or drug-induced apoptosis.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 42, March 2001 (2001-03-01), pages 552, XP002251122, ISSN: 0197-016X *
FULDA SIMONE ET AL: "Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.", NATURE MEDICINE, vol. 8, no. 8, August 2002 (2002-08-01), pages 808 - 815, XP002251127, ISSN: 1078-8956 *
FULDA SIMONE ET AL: "Smac peptides or Smac gene transfer as a novel strategy to overcome resistance against TRAIL- or drug-induced apoptosis.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), pages 527 - 528, XP002251124, ISSN: 0197-016X *
FULDA SIMONE ET AL: "Smac release from mitochondria bypasses the Bcl-2 inhibition and sensitizes tumor cells for death receptor or drug-induced apoptosis.", BLOOD NOVEMBER 16, 2001, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), pages 572a - 573a, XP002251123, ISSN: 0006-4971 *
HOLCIK M ET AL: "TRANSLATION UPREGULATION OF X-LINKED INHIBITOR OF APOPTOSIS (XIAP) INCREASES RESISTANCE TO RADIATION INDUCED CELL DEATH", ONCOGENE, vol. 19, no. 36, 24 August 2000 (2000-08-24), pages 4174 - 4177, XP008007068, ISSN: 0950-9232 *
IGNEY FREDERIK H ET AL: "Death and anti-death: Tumour resistance to apoptosis.", NATURE REVIEWS CANCER, vol. 2, no. 4, 20 April 2002 (2002-04-20), pages 277 - 288, XP002251126, ISSN: 1474-175X *
J. SILKE ET AL.: "The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites", JOURNAL OF CELL BIOLOGY, vol. 157, no. 1, 1 April 2002 (2002-04-01), pages 115 - 124, XP002272040, ISSN: 0021-9525 *
JOHNSTONE RICKY W ET AL: "Apoptosis: A link between cancer genetics and chemotherapy.", CELL, vol. 108, no. 2, 25 January 2002 (2002-01-25), pages 153 - 164, XP002251125, ISSN: 0092-8674 *
SCHWARZE S ET AL: "In vivo protein transduction: delivery of a biologically active protein into the mouse", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 285, no. 5433, 3 September 1999 (1999-09-03), pages 1569 - 1572, XP002140133, ISSN: 0036-8075 *
SRINIVASULA S M ET AL: "A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis", NATURE, vol. 410, 1 March 2001 (2001-03-01), pages 112 - 116, XP002962286, ISSN: 0028-0836 *
VERHAGEN A M ET AL: "HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 1, 4 January 2002 (2002-01-04), pages 445 - 454, XP002957689, ISSN: 0021-9258 *
VERHAGEN ANNE M ET AL: "Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins", CELL, vol. 102, no. 1, 7 July 2000 (2000-07-07), pages 43 - 53, XP002175397, ISSN: 0092-8674 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076366B2 (en) 2009-01-15 2011-12-13 Cephalon, Inc. Forms of bendamustine free base

Also Published As

Publication number Publication date
EP1495124A2 (en) 2005-01-12
WO2003086470A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
WO2003086470A3 (en) Smac-peptides as therapeutics against cancer and autoimmune diseases
PH12020552065A1 (en) Ibrutinib combination therapy
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
MX2007004551A (en) Thiadiazole compounds and methods of use.
WO2018141002A3 (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
RS20150135A1 (en) Treatment with anti-vegf antibodies
NZ544472A (en) Compounds and therapeutical use thereof
RS48804A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
EA201070013A1 (en) SALTS of the JANUS-KINASE INHIBITOR (R) -3- (4- (7H-PYRROLO [2,3-d] PYRIMIDIN-4-IL) -1H-PYRAZOL-1-IL) -3-CYCLOPENTYL-PROPHANNITRY
MXPA05012155A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases.
MXPA05008478A (en) Substituted heterocycles.
NO20071426L (en) Cancer combination therapy including AZD2171 and Imatinib
NO20071428L (en) Combination containing ZD6474 and Imatinib
WO2007015935A3 (en) Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
BRPI0513513A (en) compound or a pharmaceutically acceptable salt thereof, process for preparing it, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and methods for producing an eg5 inhibitory effect and an anticancer effect on a warm-blooded animal , and to treat carcinomas in a warm-blooded animal
EP2004637A1 (en) Substituted ring fused azines and their use in cancer therapy
WO2005024755A3 (en) Medicaments for the treatment of neurodegenerative disorders or diabetes
WO2005046593A3 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
TNSN07294A1 (en) Treatment of metastasized tumors
WO2004096159A3 (en) Saposin c-dops: a novel anti-tumor agent
EP1636160A4 (en) Novel therapeautic agents for the treatment of cancer, metabolic diseases and skin disorders
GB0416508D0 (en) Therapeutic agents
MX2009003532A (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin.
IL164564A0 (en) Combination therapy for the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003583486

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003722503

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003722503

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10511037

Country of ref document: US